NBIX

Neurocrine Biosciences Inc.

Price

$155.13

return (12m)

7.88%

p/e

22.05

p/bv

4.21

DIVIDEND YIELD

0.00%

NBIX price

Neurocrine

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment NBIX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-5.42%

3 months

-3.56%

1 year

7.88%

2 years

29.09%

5 years

64.25%

10 years

202.99%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals NBIX

Valuation

P/E

22.05

Sector -3.78

Industry -3.78

P/BV

4.21

Sector 2.17

Industry 2.17

P/Revenue (PSR)

4.61

Sector 2.19

Industry 2.19

EV/EBITDA

79.87

Sector -220.59

Industry -220.59

EV/EBIT

91.87

Sector -47.42

Industry -47.42

P/EBITDA

17.97

Sector -21.40

Industry -21.40

P/EBIT

19.01

Sector -31.65

Industry -31.65

P/Total Assets

2.90

Sector 1.27

Industry 1.27

P/Net Current Assets

-555.61

Sector -10.98

Industry -10.98

P/Working Capital

20.39

Sector -189.70

Industry -189.70

EPS

6.99

Sector -1.77

Industry -1.77

BVPS

36.57

Sector 2.04

Industry 2.04

Efficiency

Gross Margin

97.94%

Sector 41.04%

Industry 41.04%

EBITDA Margin

19.80%

Sector -17,787.58%

Industry -17,787.58%

EBIT Margin

17.22%

Sector -4,203,887.15%

Industry -4,203,887.15%

Operating Margin

23.56%

Sector -34.94%

Industry -34.94%

Net Profit Margins

20.91%

Sector -35.70%

Industry -35.70%

Asset Turnover

0.18

Sector 0.03

Industry 0.03

Profitability

ROE

19.10%

Sector -56.49%

Industry -56.49%

ROA

13.16%

Sector -59.78%

Industry -59.78%

ROIC

14.14%

Sector -2,345.18%

Industry -2,345.18%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

1.87

Sector 2.92

Industry 2.92

Net Debt / EBITDA

-2.05

Sector -14,656,762.33

Industry -14,656,762.33

Net Debt / EBIT

-2.36

Sector -8.32

Industry -8.32

Net Debt / Equity

-0.11

Sector -32,504.62

Industry -32,504.62

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

0.69

Sector 0.46

Industry 0.46

Liabilities/Assets

0.31

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

24.38%

Sector -

Industry -

5Y Earnings CAGR

51.09%

Sector -

Industry -

Fundamentals NBIX

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Neurocrine ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$155.13

Fair Value

$75.84

Upside Return potential.

-51.11%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
NBIX Neurocrine Biosciences Inc.	$155.13	7.65%	0.00%	22.05	4.21	19.10%	20.91%
JNJ Johnson & Johnson	$269.12	55.37%	1.90%	31.48	7.79	24.76%	21.48%
PFE Pfizer Inc.	$27.79	19.56%	6.01%	37.36	1.91	5.11%	6.86%
ABBV AbbVie Inc.	$248.78	20.77%	2.66%	72.11	-76.75	-106.44%	9.81%
NVO Novo Nordisk A/S	$45.16	-12.69%	3.97%	11.43	6.07	53.11%	35.32%
MRK Merck & Co. Inc.	$148.46	82.11%	2.24%	116.76	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$160.04	0.22%	1.98%	19.30	4.97	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$65.15	44.76%	3.75%	14.74	6.13	41.55%	18.85%
ZTS Zoetis Inc.	$74.39	-50.55%	2.76%	11.95	10.04	84.02%	27.77%
AMGN Amgen Inc.	$394.27	43.99%	2.25%	26.93	20.14	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$810.31	46.18%	0.44%	19.82	2.71	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$108.31	44.55%	0.00%	31.19	89.88	288.13%	24.86%
MCK McKesson Corporation	$889.12	30.01%	0.36%	20.52	-28.15	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$546.12	37.87%	0.00%	31.75	6.91	21.76%	35.00%
CAH Cardinal Health Inc.	$241.34	63.43%	0.83%	37.62	-21.79	-57.93%	0.62%
ARGX argenx SE	$1,005.55	33.93%	0.00%	3.11	3.48	112.18%	44.41%
HRMY Harmony Biosciences Holdings Inc.	$42.07	16.89%	0.00%	13.47	2.44	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

NBIX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Neurocrine

Neurocrine Biosciences Inc.

Average Investor10 user rating

4.0 (5 people)

United States

34 years

Founded: 1992

1996

Time since IPO - 30 years

845

Employees

Neurocrine Biosciences Inc. (United States) is listed on the Nasdaq and has a market capitalization of $15.56 billion, with shareholders equity totaling $3.69 billion.

The company employs approximately 845 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Neurocrine Biosciences Inc. reported $3.37 billion in revenue, generating net income of $705.50 million.

Key financial metrics include a P/E ratio of 22.05, a price-to-book (P/B) ratio of 4.21, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker NBIX.

Market cap

$15.56 billion

Net worth

$3.69 billion

$3,693,600,000.00

Assets

$5.36 billion

$5,359,100,000.00

Total Shares Outstanding

101.00 million

101,000,000

Average Daily Trading Volume

$1.26 million

$1,260,785.94

Sector

Health Care

Industry

Biotechnology

NBIX

NBIX revenue and profits

Financial Results NBIX

DRAG THE FRAME TO SEE MORE DATA

NBIX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$889.12 26,66% (12M)

P/E

20.52

0.36%

ROE

-137.16%

P/BV

-28.15

CAH - Cardinal Health

$241.34 61,93% (12M)

P/E

37.62

0.83%

ROE

-57.93%

P/BV

-21.79

JNJ - Johnson & Johnson

$269.12 55,53% (12M)

P/E

31.48

1.90%

ROE

24.76%

P/BV

7.79

ABBV - AbbVie

$248.78 22,00% (12M)

P/E

72.11

2.66%

ROE

-106.44%

P/BV

-76.75

MRK - Merck & Co.

$148.46 82,33% (12M)

P/E

116.76

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$160.04 0,73% (12M)

P/E

19.30

1.98%

ROE

25.77%

P/BV

4.97

PFE - Pfizer

$27.79 20,39% (12M)

P/E

37.36

6.01%

ROE

5.11%

P/BV

1.91

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$889.12 26,66% (12 M)

P/L

20.52

0.36%

ROE

-137.16%

P/VP

-28.15

CAH - Cardinal Health

$241.34 61,93% (12 M)

P/L

37.62

0.83%

ROE

-57.93%

P/VP

-21.79

JNJ - Johnson & Johnson

$269.12 55,53% (12 M)

P/L

31.48

1.90%

ROE

24.76%

P/VP

7.79

ABBV - AbbVie

$248.78 22,00% (12 M)

P/L

72.11

2.66%

ROE

-106.44%

P/VP

-76.75

MRK - Merck & Co.

$148.46 82,33% (12 M)

P/L

116.76

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$160.04 0,73% (12 M)

P/L

19.30

1.98%

ROE

25.77%

P/VP

4.97

PFE - Pfizer

$27.79 20,39% (12 M)

P/L

37.36

6.01%

ROE

5.11%

P/VP

1.91

Frequently Asked Questions

What is the price of Neurocrine (NBIX) today?

A cotação de Neurocrine (NBIX) hoje está em US$ 155.13, com uma variação de 7.88% em relação ao último ano. A cotação de Neurocrine (NBIX) iniciou o ano negociando na casa dos US$ 141.83 e hoje está em US$ 155.13. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Neurocrine (NBIX) e dados de ações do Ibovespa e mercados internacionais.

Quando Neurocrine (NBIX) paga dividendos?

Neurocrine (NBIX) não distribuiu dividendos no último ano.

Is Neurocrine (NBIX) a good investment?

Atualmente, Neurocrine (NBIX) está cotada a US$ 155.13, com um P/L de 22.05, representando um desvio de 4,352% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 7.88 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 7.88%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Neurocrine (NBIX) stock?

Investir em ações de Neurocrine (NBIX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Neurocrine (NBIX) yield today?

A rentabilidade de Neurocrine (NBIX) foi de -5.42% no último mês, 7.88% no último ano e 64.25% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Neurocrine (NBIX) hoje, o investimento total seria de US$ 15,513.00, com base na cotação atual de US$ 155.13.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 16,735.42
Em 5 anos: US$ 25,480.10
Em 10 anos: US$ 47,002.84

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

NBIX

Neurocrine Biosciences Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment NBIX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING NBIX WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Neurocrine

Neurocrine Biosciences Inc.

United States

34 years

1996

845

PROFIT X PRICE NBIX

Financial Results NBIX

NBIX cash flow

Asset, Revenue and Profit Growth - NBIX

NBIX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions